Loading page…
Healthcare
BridgeBio Pharma, Inc. displays an AlphaScore of 25/100 in the Healthcare sector, carrying a caution signal and a market capitalization of $12.78 billion. Relevant metrics include an exceptionally high gross margin of 95.82% and a severe net margin of -97.03%. A primary strength is its superior product gross profitability, while a substantial risk lies in its deeply negative profitability margins. Evidence is limited to the provided snapshot date of 2026-10-11.
Written 11/10/2026, 00:43:07 UTC · Snapshot 11/10/2026